orb1305225

1-tert-butyl-3-[2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea

219580-11-7 C28H41N7O3

Properties

orb1305225 molecular structure
CAS Number
219580-11-7
Formula
C28H41N7O3
Molecular Weight
523.7 g/mol
IUPAC Name
1-tert-butyl-3-[2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
InChI Key
DXCUKNQANPLTEJ-UHFFFAOYSA-N

Also Known As

PD173074 PD 173074 PD-173074 A4TLL8634Y 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea CHEBI:63448 DTXSID30176363 N-(2-((4-(DIETHYLAMINO)BUTYL)AMINO)-6-(3,5-DIMETHOXYPHENYL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-N'-(1,1-DIMETHYLETHYL)UREA N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea 1-tert-butyl-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido(2,3-d)pyrimidin-7-yl)urea

Description

PD173074 is a member of the class of ureas that is 1-tert-butylurea in which one of the hydrogens attached to N3 is substituted by a pyrido[2,3-d]pyrimidin-7-yl group, which is itself substituted at positions 2 and 6 by a 4-(diethylamino)butyl]amino group and a 3,5-dimethoxyphenyl group, respectively. It is a FGF/VEGF receptor tyrosine kinase inhibitor. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and a fibroblast growth factor receptor antagonist. It is an aromatic amine, a pyridopyrimidine, a member of ureas, a tertiary amino compound, a dimethoxybenzene and a biaryl. It is functionally related to a PD-166866.

Suppliers

No suppliers have listed orb1305225 yet — but we’ll source it for you.

Tell us what you need and our team will reach out to our supplier network on your behalf. It’s free, with no obligation.

Request a quote
Supply orb1305225? Claim this listing →

Request a Quote

No suppliers listed yet — we’ll source orb1305225 for you.

Free for buyers. We’ll email you as soon as we have quotes — typically within 1–2 working days.